The Latest Cardiac and Vascular News
Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse® Pulsed Electro Magnetic Frequency (PEMF) proprietary assets. This may include, but is not limited to, discussions with investment bankers, equity fund […]
More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and […]
Agreement Provides Flexible Access to Funding at a Lower Cost of Capital Los Angeles, CA, May 26, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) announced today it has executed a new Equity Line Purchase Agreement with Cavalry Fund I, LP (“Cavalry”) to sell up […]
